Two NIH Grants Fund Studies of Therapy Options to Treat Lung Disease and Triple Negative Breast Cancer
With the help of two major grants, Dr. Marina Holz, The Doris and Ira Kukin Professor of Biology at Yeshiva University’s Stern College for Women, is exploring new treatment options for patients with rare and little-understood forms of cancer.
This fall, Holz will partner with colleagues at the University of Cincinnati in a new clinical trial that examines the potential role of a drug combination therapy to eliminate lymphangioleiomyomatosis (LAM) cells, funded by a three-year, $712,442 grant from the National Institute of Health’s (NIH) Heart, Lung, and Blood Institute. LAM is a rare but serious lung disease that occurs primarily in women of childbearing age as a low-grade tumor in which the abnormal tumor cells grow out of control and spread to restricted areas in the body, including the lungs, kidneys, lymph nodes, blood vessels and lymphatics.
The trial will look at the safety and efficacy of a combined therapy using sirolimus and resveratrol as a potential remission-inducing treatment option for patients with LAM. Sirolimus is a drug approved by the Food and Drug Administration that suppresses cell growth in LAM patients and…